atai Life Sciences (NASDAQ:ATAI, ETR:9VC)’ chief scientific officer Dr Srinivas Rao joined Proactive to discuss the company's latest clinical trial results. Dr Rao detailed the positive outcomes from the Phase 1B trial of the VLS-01 (oral DMT) program, emphasizing the drug's excellent tolerability and potential as a best-in-class treatment option. Proactive: You're out with some exciting clinical trial results today. Can you tell us about the VLS-01 program? What do today's Phase 1b results mean? Srinivas R ...